-
Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate
Monday, June 21, 2021 - 11:35am | 166Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals...
-
Janney: 4 Reasons Why Selecta Biosciences Is 'Significantly Undervalued'
Wednesday, June 27, 2018 - 12:26pm | 436Selecta Biosciences Inc (NASDAQ: SELB) shares plummeted in November 2017 from the $20 level and have yet to recover. The stock should not only recoup all of its losses, but trade at new all-time highs, according to Janney. The Analyst Janney's Yun Zhong initiated coverage of Selecta...